Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Advisory Committees

September 23, 2011: Cellular, Tissue and Gene Therapies Advisory Committee Meeting Draft Agenda

Food and Drug Administration
Center for Biologics Evaluation and Research
Cellular, Tissue and Gene Therapies Advisory Committee
Meeting # 53, September 23, 2011
Hilton Hotel, Gaithersburg, MD

Draft Agenda

8:00 a.m.Call to Order and Introduction of Committee
 Conflict of Interest Statement
8:15Regulation of Humanitarian Device Exemption (HDE) products

Open Committee Discussion: HDE BH110018, CliniMACS® CD34 Selection System, Miltenyi Biotec, for processing allogeneic HLA-matched hematopoietic progenitor cells-apheresis (HPC-C) from a related donor to obtain a CD34 + cell population intended for hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional graft-vs-host disease (GVHD) prophylaxis in patients with acute myelogenous leukemia in first or second morphologic complete remission


Sponsor Presentation
Miltenyi Biotec, Incorporated

10:20FDA Presentation
11:35Open Public Hearing
12:35 p.mLunch

Committee Discussion of Questions and Vote

5:00 p.m.Adjourn

Page Last Updated: 08/12/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English